Inclusion Criteria:

- Histologically confirmed germ cell tumor (seminoma or non-seminoma) with measurable
metastatic disease either by radiography (at a site which has previously not been
irradiated) or elevation of alpha fetoprotein (AFP) and/or elevation of beta-human
chorionic gonadotropin (beta-HCG);

- Patient previously treated with standard BEP (3 or 4 cycles) with relapse 1 months or
more after favorable response on previous chemotherapy (CR or PR)

- Male

- Age greater than or equal to 18 years;

- Performance status 0,1,2 or 3

- WBC > 3000 mill/l, ANC > 1500 mill/l, platelet count > 100.000 mill/l; serum
bilirubin < 1.5 x the upper limit of normal;

- Adequate renal function (Glomerular Filtration Rate (GFR) >60 ml/min). GFR will be
assessed by direct measurement (EDTA clearance or creatinine clearance)

- signed informed consent;

Exclusion Criteria:

- Uncontrolled active severe clinical infection (CTC grade 3 or 4).

- Serious concomitant systemic disorders incompatible with the study (at the discretion
of the investigator), including expected difficulty of follow-up related to mental
disorders.

- Grade 2 or greater peripheral neuropathy according to the CTC, version 3.0.

- Second malignancy other than basal or squamous cell skin cancer.